Taken together, our data showed that SIK2 accelerates ovarian cancer cell motility and metastasis by promoting MYLK/MYL2 phosphorylation and that targeting SIK2 inhibits ovarian cancer metastasis in vivo (Fig. 7H). Here, MYL2 is linked to ovarian carcinoma.